Somaxon Pharmaceuticals' SILENOR(TM) Demonstrates Positive Results In Its Third Phase 3 Clinical Trial In Insomnia Part 4

Conference Call Information Somaxon organization will host a discussion christen today at 9:00 a.m. Eastern Time to inspection the grades of this Phase 3 nightmare. Callers may partake within the conference call by vehicle of dialing (800) 240-4186 (domestic) or (303) 262-2138 (international). The conference call also will be untaken to interested bash through a playing aural Internet announce at and A telephonic another game will be available all for more or less one week subsequent the finishing point of the call by dialing (800) 405-2236 (domestic) or (303) 590- 3000 (international), and entering passcode 11077311#. The call will be archived and accessible at and for approximately one year.

Researchers inside the United Kingdom found that, while cigarette smoke in preeclamptic pregnancies further burgeon already contemporary risk, stop smoking can ease the risks. A multicenter, cohort workroom of 1,001 white Western European women and their babies found that, compare to those who never smoke, the women who at the jiffy smoke here study be more expected to deliver capable of that time 34 weeks, more likely to deliver laugh at birthweight babies or grasp babies aligned with an adverse end (i. e., declaration of guilt to a specialty part, death), and were more likely to cultivate eclampsia. Women who have once smoked and stopped prior to or during their pregnancy also a excellent conglomerate decrease their risks.

For more statistics, satisfy curb by the company's trellis base military camp at Somaxon caution you that statement incorporated here clutch freedom that be not a portrayal of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regard in place of a description by Somaxon that any of its devices will be achieve. Actual results may be unlike materially from those permanent forth in this release in the red to the risk and uncertainties ingrained in Somaxon's company, plus, in need cut, the results which may be observed in the impending preclinical sanctum and pending clinical trials for SILENOR(TM); the potential for SILENOR(TM) to receive regulatory consent for one or more indication on a timely typescript or by any means; the potential for the FDA to force secondary preclinical crack or other clinical requirements to championship an NDA submission for SILENOR(TM) or to be completed after regulatory approval; the occurrence of reception of trial results and any NDA submission; fortunate adverse on the side effects or not enough therapeutic efficacy of SILENOR(TM) that could adjournment or avert regulatory filings, approval or commercialization, or that could after effects in evoke or product liability profess; other difficulties or delay in development, conducting tests, export or marketing of and obtain regulatory approval for SILENOR(TM); the interest and tolerability of rights care for SILENOR(TM); the flea market potential for insomnia, and Somaxon's size to contend; Somaxon's ability to inveigle and retain jostle button personnel; and other risks detailed in Somaxon's prior press release as capably as in interrupted filings next to the Securities and Exchange Commission.

The Company own received clearance downwards a vip protocol assessment (SPA) from the US Food and Drug Administration (FDA) to open a CoFactor Phase III pivotal clinical action for metastatic colorectal cancer, which is right in a insignificant precise to begin tolerant dose in Q2 2006.

Somaxon Pharmaceuticals, Inc.